A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

  • Ain, Kenneth (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date7/10/192/7/23